Intelligene INC.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
The technological advantage of Intelligene INC. lies in its mastery of the R&D capabilities required for novel RNA nucleic acid drug development and drug encapsulation and delivery systems. The Company advances selected promising nucleic acid drug candidates into clinical trials to realize its commercialization goals. Meanwhile, through the establishment of a GMP pilot plant—Process Research Center, the Company will be able to independently master the manufacturing processes for RNA nucleic acid drug delivery technology.
The content above was translated by Ai
Founded Year
2023
Unified Business No.
94072060
Status
Active
Number of Employees
21
Total Paid-in
Capital
580,000,000 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Emerging Stock Exchange(2025)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Intelligene INC. was established in June 2023, dedicated to developing innovative RNA nucleic acid drugs and building an RNA nucleic acid drug research and development platform to accelerate the development of innovative gene therapies, and striving to fulfill its commitment to improving public health and jointly addressing the challenges posed by viral infections.
The company possesses two key manufacturing technologies: lipid nanoparticle (LNP) encapsulation technology and exosome drug encapsulation technology, which enable the customization of drug carriers targeting different indications to develop more comprehensive and precise nucleic acid therapeutic drugs. Currently, its research and development focus is on drugs for infectious diseases and encapsulation carrier delivery technologies for nucleic acid drugs.
The company possesses two key manufacturing technologies: lipid nanoparticle (LNP) encapsulation technology and exosome drug encapsulation technology, which enable the customization of drug carriers targeting different indications to develop more comprehensive and precise nucleic acid therapeutic drugs. Currently, its research and development focus is on drugs for infectious diseases and encapsulation carrier delivery technologies for nucleic acid drugs.
The content above was translated by Ai
